RxDoctor Payments Data

George Sidhom, MD

Interventional Pain Medicine · Spring Hill, FLNPI 1003814435

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 56 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
  • Scilex Pharmaceuticals Inc.$128
  • Takeda Pharmaceuticals U.S.A., Inc.$102
  • Novartis$89
  • Amgen$77
  • Collegium Pharmaceutical, Inc.$55
  • plus $319 from 12 others

What the payments were for

  • Food & beverage$1,00598%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,026 in reported general payments places this provider in the 20th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$213,251
Medicare patients
224
Services billed
6,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,965$35,830
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl137$24,696
Morphine Sulfate706$16,662
MovantikNaloxegol Oxalate39$15,893
Pregabalin605$11,341
Gabapentin810$10,666
Fentanyl118$9,401
Morphine Sulfate ErMorphine Sulfate480$9,260
Naloxone Hcl114$8,170
Baclofen345$5,312
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen166$3,773
Tramadol Hcl309$2,740
Celecoxib114$2,382
Methadone Hcl163$2,341
Lidocaine27$2,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$21$41,358843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →